Different IOL calculators provided similar results in patients with a history of LASIK surgery, according to a study ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
LAS VEGAS — Max Verstappen won the Las Vegas Grand Prix on Saturday night after capturing the lead from championship leader Lando Norris at the start and never looking back. The Formula 1 cars blasted ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Working capital is a powerful indicator of the success of your business, and it can give you borrowing power. Many, or all, of the products featured on this page are from our advertising partners who ...
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
Formula 1's $2.5 billion in revenue is driven by record attendance and global viewership. Hiranmayi Srinivasan is a former Associate Editor for Investopedia. She covered personal finance topics such ...
HARTFORD, Conn. (WFSB) - Your Connecticut car tax bill should have come in the mail this week, and viewers kept asking the I-Team why they were paying more this year if their car is getting older.
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback